(Q37789177)

23 August 2017

title

Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas (English)

1 reference

23 August 2017

Patrick G. Morris

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20844972

14 July 2024

Lauren E. Abrey

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20844972

14 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20844972

14 July 2024

publication date

16 September 2010

1 reference

full work available at URL

23 August 2017

http://link.springer.com/content/pdf/10.1007/s11523-010-0160-7.pdf

file format

Portable Document Format

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1007/S11523-010-0160-7

http://link.springer.com/article/10.1007/s11523-010-0160-7/fulltext.html

14 July 2024

1 reference

https://api.crossref.org/works/10.1007/S11523-010-0160-7

http://link.springer.com/content/pdf/10.1007/s11523-010-0160-7

14 July 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1007/S11523-010-0160-7

14 July 2024

1 reference

23 August 2017

volume

5

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

193-200

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

23 August 2017

cites work

1 reference

12 December 2020

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

1 reference

12 December 2020

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

1 reference

12 December 2020

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

12 December 2020

Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

1 reference

12 December 2020

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

1 reference

12 December 2020

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

12 December 2020

Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations

1 reference

12 December 2020

Endothelial cell KIT expression in human tumours.

1 reference

12 December 2020

The protein kinase complement of the human genome

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

12 December 2020

Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.

1 reference

12 December 2020

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

1 reference

12 December 2020

Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme

1 reference

12 December 2020

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

1 reference

12 December 2020

A quantitative analysis of kinase inhibitor selectivity

1 reference

12 December 2020

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

1 reference

12 December 2020

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

1 reference

12 December 2020

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

12 December 2020

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

1 reference

12 December 2020

CD117 expression in glial tumors

1 reference

12 December 2020

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

1 reference

12 December 2020

Immunohistochemical detection of the gene product of Rous sarcoma virus in human brain tumors

1 reference

12 December 2020

Molecular alterations of KIT oncogene in gliomas.

1 reference

12 December 2020

PDGFR inhibition in brain tumours--oft expectation fails where most it promises.

1 reference

12 December 2020

Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.

1 reference

12 December 2020

Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines

1 reference

12 December 2020

Role of platelet-derived growth factors in physiology and medicine

1 reference

12 December 2020

Prevalence of KIT expression in human tumors

1 reference

12 December 2020

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

12 December 2020

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

1 reference

12 December 2020

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma

1 reference

12 December 2020

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

1 reference

12 December 2020

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

1 reference

12 December 2020

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

1 reference

12 December 2020

Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas

1 reference

12 December 2020

Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops

1 reference

12 December 2020

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

Identifiers

DOI

1 reference

23 August 2017

1 reference